• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    10/13/23 5:31:42 PM ET
    $ARTL
    $BLPH
    $CING
    $EIGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email

    Gainers

    • Bellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million.
    • Cingulate (NASDAQ:CING) stock increased by 12.59% to $0.58. The company's market cap stands at $10.0 million.
    • Rain Oncology (NASDAQ:RAIN) stock rose 11.11% to $1.1. Rain Oncology's trading volume hit 98.3K shares by close, accounting for 45.0% of its average volume over the last 100 days. The company's market cap stands at $40.0 million.
    • Artelo Biosciences (NASDAQ:ARTL) shares rose 9.72% to $1.58. The market value of their outstanding shares is at $4.5 million.
    • Processa Pharma (NASDAQ:PCSA) shares moved upwards by 8.37% to $0.52. This security traded at a volume of 751.1K shares come close, making up 347.2% of its average volume over the last 100 days. The company's market cap stands at $12.8 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock rose 7.78% to $0.27. The company's market cap stands at $11.9 million.

    Losers

    • Eloxx Pharmaceuticals (NASDAQ:ELOX) stock decreased by 17.5% to $3.15 during Friday's after-market session. The market value of their outstanding shares is at $9.6 million.
    • TRACON Pharma (NASDAQ:TCON) stock declined by 7.66% to $0.18. At the close, TRACON Pharma's trading volume reached 9.9 million shares. This is 1727.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.4 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock declined by 7.41% to $1.0. The market value of their outstanding shares is at $3.6 million.
    • Purple Biotech (NASDAQ:PPBT) shares fell 6.26% to $1.2. The market value of their outstanding shares is at $25.6 million.
    • RVL Pharmaceuticals (NASDAQ:RVLP) stock declined by 6.17% to $0.07. At the close, RVL Pharmaceuticals's trading volume reached 8.8 million shares. This is 53.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.6 million.
    • OpGen (NASDAQ:OPGN) shares declined by 6.16% to $0.77. Today's trading volume for this security ended up closing at 2.1 million shares, which is 65.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $6.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL
    $BLPH
    $CING
    $EIGR

    CompanyDatePrice TargetRatingAnalyst
    Artelo Biosciences Inc.
    $ARTL
    7/8/2025$20.00Hold → Buy
    D. Boral Capital
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Processa Pharmaceuticals Inc.
    $PCSA
    4/25/2024$8.00Buy
    H.C. Wainwright
    Cingulate Inc.
    $CING
    12/22/2023Buy → Hold
    Laidlaw
    Rain Enhancement Technologies Holdco Inc.
    $RAIN
    5/30/2023Buy → Neutral
    ROTH MKM
    Rain Enhancement Technologies Holdco Inc.
    $RAIN
    3/21/2023$11.00Outperform
    SVB Securities
    Rain Enhancement Technologies Holdco Inc.
    $RAIN
    1/31/2023$21.00Buy
    ROTH Capital
    Rain Enhancement Technologies Holdco Inc.
    $RAIN
    1/23/2023$18.00Buy
    Mizuho
    More analyst ratings

    $ARTL
    $BLPH
    $CING
    $EIGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artelo Biosciences upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00

    7/8/25 8:21:40 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on AirGate PCS with a new price target

    H.C. Wainwright initiated coverage of AirGate PCS with a rating of Buy and set a new price target of $8.00

    4/25/24 6:22:04 AM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gagnon Robert E.

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/18/26 6:06:33 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:25:06 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    SEC Filings

    View All

    Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    3/18/26 5:00:16 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Cingulate Inc.

    DEFA14A - Cingulate Inc. (0001862150) (Filer)

    3/18/26 4:30:04 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Processa Pharmaceuticals Inc.

    10-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    3/18/26 4:05:57 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today's action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. Artelo Biosciences (NASDAQ:ARTL) expands ART27.13's clinical footprint into ophthalmology through a fully funded investigator-initiated study agree

    3/18/26 10:41:39 AM ET
    $AIM
    $ARTL
    $YYGH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Professional Services

    Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

    BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ:ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial (IST) is backed by Glaucoma UK and the HSC R&D Division, with first patient enrollment anticipated in Q2 2026. The announcement represents a significant pipeline diversification for the San Diego-based clinical-stage biopharmaceutical company — and one that does not require dilutive equity financing from shareholders. A $16.3 Billion Market Growing Faster Than Its Treatment Options The global glaucoma market was valued at USD 9.46 billion in 202

    3/18/26 8:07:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i

    3/18/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    Leadership Updates

    Live Leadership Updates

    View All

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $BLPH
    $CING
    $EIGR
    Financials

    Live finance-specific insights

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care